Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children ’s Oncology Group phase 1 consortium study (ADVL1212)

ConclusionsThe RP2D of crizotinib FCs in combination with cyclophosphamide and topotecan was 215  mg/m2/dose BID. The oral solution of crizotinib was not palatable in this patient population. Crizotinib cMS was palatable; however, patients experienced increased toxicity that was not explained by the relative bioavailability or exposure and warrants further investigation.Clinical trial registryThe trial is registered as NCT01606878 at Clinicaltrials.gov.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research